NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference

NEO 11.08.2024

Full Press ReleaseSEC FilingsOur NEO Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
  • 01.14.2025 - Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
  • 01.10.2025 - NeoGenomics Announces Chief Executive Officer Succession

Recent Filings

  • 01.16.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.15.2025 - 8-K Current report
  • 01.15.2025 - EX-99.1 EX-99.1

NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference

November 08, 2024 7:00am ESTDownload as PDF

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO),a leading oncology testing services company, will attend the Piper Sandler 36thAnnual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.

The presentation will be webcast live and accessible online via thislink. A replay will be available on the Investor Relations section of the Company’s website atir.neogenomics.com.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241108197311/en/

Investor ContactKendra Sweeneykendra.sweeney@neogenomics.com

Media ContactAndrea Sampsonasampson@sampsonprgroup.com

Source: NeoGenomics, Inc.

Released November 8, 2024

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com